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Abstract: Cardiac remodeling occurs frequently in chronic kidney disease patients and affects quality
of life and survival. Current treatment options are highly inadequate. As kidney function declines,
numerous metabolic pathways are disturbed. Kidney and heart functions are highly connected
by organ crosstalk. Among others, altered volume and pressure status, ischemia, accelerated
atherosclerosis and arteriosclerosis, disturbed mineral metabolism, renal anemia, activation of the
renin-angiotensin system, uremic toxins, oxidative stress and upregulation of cytokines stress the
sensitive interplay between different cardiac cell types. The fatal consequences are left-ventricular
hypertrophy, fibrosis and capillary rarefaction, which lead to systolic and/or diastolic left-ventricular
failure. Furthermore, fibrosis triggers electric instability and sudden cardiac death. This review
focuses on established and potential pathophysiological cardiorenal crosstalk mechanisms that drive
uremia-induced senescence and disease progression, including potential known targets and animal
models that might help us to better understand the disease and to identify novel therapeutics.
Keywords: uremia; uremic cardiomyopathy; organ crosstalk; cardiorenal syndrome; chronic kidney
disease; left-ventricular hypertrophy; heart failure; cardiac fibrosis
Key Contribution: Here, we provide a most recent overview on the proposed mechanisms in
organ crosstalk from kidney disease to myocardium, underlying cellular mechanisms and available
mouse models. We thereby aim to offer potential therapeutic target sites in this understudied
disease condition.
1. Chronic Kidney Disease
Chronic kidney disease (CKD) affects an increasing number of patients worldwide and is associated
with dramatically increased morbidity and mortality [1,2]. Recent data suggest that CKD currently
affects more than 10% of the population in the developed world [3,4].
Diabetes mellitus and high blood pressure are among the most prevalent risk factors for the
development of CKD and are responsible for the majority of cases. Other conditions that affect the
kidneys are glomerulonephritis, the third most common type of kidney disease, inherited diseases, such
as polycystic kidney disease, and loss of renal tissue due to infections, malformations or urinary tract
obstruction. Repeated episodes of acute kidney injury and certain therapeutics, such as non-steroidal
anti-inflammatory drugs (NSAIDs) can also contribute to CKD [2].
In end-stage renal failure, dialysis and subsequent kidney transplantation are the only available
treatment options apart from palliative care. However, not all patients qualify for kidney transplantation
and transplant waiting times are often long. Thus, patients usually undergo many years of dialysis
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treatment. Longstanding uremia in turn promotes cardiovascular disease. Consequently, the leading
causes of death in dialysis patients are sudden cardiac death and recurrent heart failure due to cardiac
and vascular remodeling [5].
Cellular Crosstalk in the Heart
The mammalian heart is a highly interactive complex of cardiac muscle cells, extracellular
matrix (ECM) and vessels. Other essential cell types include endothelial cells, fibroblasts, vascular
smooth muscle cells and perivascular cells [6,7]. Studies, using state-of-the-art methods such as
single-cell transcriptomics, suggest that all cardiac cell types communicate vigorously with one another
in homeostasis and disease [8–10]. Each cardiomyocyte is in physical contact with at least one
capillary, allowing mechanical and paracrine crosstalk between at least four key cell types, namely,
cardiomyocytes, endothelial cells, vascular smooth muscle cells (VSMCs) and pericytes/fibroblasts [11].
Cardiomyocytes crosstalk with endothelial cells and fibroblasts by secreting various specific growth
factors [7]. Various lines of evidence suggest that endothelial cells crosstalk with cardiomyocytes and
are key players in angiogenesis and vasomotor tone control by secreting angiocrine factors such as nitric
oxide or endothelin-1 [12]. One example of paracrine intercellular crosstalk inside the myocardium is
vasomotion. Endothelial cells are directly exposed to shear stress, contrary to VSMCs. To facilitate
vasomotion, endothelial cells release nitric oxide in response to shear stress, thus signaling to the
VSMCs to dilate. The cardiac morphology and function can be affected by further external and
internal stimuli.
2. Pathology and Pathophysiology of the Cardiorenal Syndrome
Kidney and cardiac health are highly linked to each other, with diseases of either organ affecting
the other organ. In the following, we aim to give an overview of the mechanisms and relevant
factors that have been reported to be involved in cardiac remodeling due to kidney injury, i.e.,
cardiorenal syndrome.
The presence of CKD and end-stage renal disease (ESRD) leads to cardiac remodeling with
hypertrophy, fibrosis and capillary loss [13]. Uremic cardiomyopathy affects about 80% of hemodialysis
patients [14] and is the main cause of death in this cohort. A similar prevalence has even been
reported in pediatric uremic patients [15] who presumably lack traditional atherosclerotic risk factors.
The comorbidities in CKD patients that contribute to cardiovascular remodeling are atherosclerosis,
hyperlipidemia, diabetes and/or hypertension, but also include a plethora of so-called non-traditional
cardiovascular risk factors such as those discussed below and summarized in Table 1. These stimuli
exacerbate the pathophysiological cardiac changes, including left-ventricular hypertrophy (LVH),
diffuse interstitial fibrosis and capillary rarefaction leading to systolic and diastolic dysfunction. In
this review, we consider these cardiac abnormalities that frequently occur in patients with CKD as
uremic cardiomyopathy.
2.1. Left-Ventricular Hypertrophy in CKD
LVH is an independent predictor of cardiac death in dialysis patients. LVH can occur early in
the course of CKD, even when the glomerular filtration rate (GFR) is still normal [16]. Once GFR is
reduced, myocytes enlarge and cardiomyocytes expand, leading to LVH [17]. Cardiomyocytes are the
major cell type, comprising about 70–85% of the total volume. They generate contractility by cyclic
calcium fluxes [17,18]. Fibroblasts secrete collagen precursors and matrix metalloproteinases (MMPs)
and thereby actively remodel the ECM [17–19]. The ECM embeds the myocytes and non-myocytes.
Collagen is the most abundant protein here [19]. These structural changes are closely related to a
functional impairment of the left ventricle causing diastolic dysfunction [20] while systolic function
may, at least initially, remain normal [21]. LVH can be a consequence of increased preload due to
hypervolemia or increased afterload due to increased peripheral resistance or hypertension, which are
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both very common in CKD. Further factors involved in the pathogenesis of LVH might be high cardiac
output due to anemia or large arteriovenous fistulas for dialysis access [18,21].
2.2. Cardiac Fibrosis
In CKD patients, myocardial fibrosis is a pathologic process that occurs together with LVH. One
hallmark of myocardial fibrosis is a marked increase in the production of extracellular matrix, especially
collagens, which impair diastolic filling due to increased stiffness of the left ventricle, but they may
also affect systolic function since functional myocytes are replaced by fibrotic scar tissue [22,23].
The main causes of myocardial fibrosis are hemodynamic alterations and disturbed secretion of
various systemic soluble factors. A primary factor leading to myocardial fibrosis in CKD patients is
hypertension, which is mainly associated with pressure overload. Factors related to hemodynamic
alterations in CKD patients like senescence, ischemia, catecholamines, angiotensin II and aldosterone
further promote the development of cardiac fibrosis [21]. Arterial stiffening is accelerated in the
presence of CKD and is caused by a loss of elastic fibers and vascular calcification [24]. Increased
vascular stiffness leads to increased cardiac afterload, which promotes cardiac hypertrophy and
fibrosis [21,25].
However, during CKD progression, left ventricular remodeling has been found to occur even
earlier than changes in large arteries [26]. This might be explained by a range of factors and mechanisms
including uremic toxins, TGF-β and other growth factors. In addition to the role of hemodynamic
changes in the development of cardiac fibrosis, non-hemodynamic factors related to the uremic milieu,
such as overactivity of the renin-angiotensin-aldosterone system, FGF-23, parathyroid hormone,
endothelin, increased sympathetic nerve discharge and increased plasma catecholamines might also
play an important role [21,27].
Perivascular mesenchymal cells surround the VSMC layer in the so-called adventitia of larger
arteries but are also present as pericytes around the vasa vasorum and in direct contact with endothelial
cells of both the large arteries and micro-vessels. They play a role in vasomotion, homeostasis and
permeability of the vasculature [11]. The heterogeneity of perivascular cells has been unclear for
many years, but recent single-cell RNA-sequencing data suggest that various, previously unknown,
perivascular mesenchymal populations exist [28,29]. We have reported that Gli1 marks a specific
perivascular cell type that drives cardiac fibrosis and vascular calcification [30,31]. Gli1+ cells are a
subset of cardiac interstitial PDGFRβ+ cells, but are mostly distinct from cardiac NG2+ pericytes [31].
However, the complex system of the cardiac perivascular cell types remains unclear, and single-cell
experiments are needed to shed light on their heterogeneity and the role they play in homeostasis
and disease.
2.3. Capillary Rarefaction
Endothelial cells line blood or lymphatic vessels and are the most abundant cells of the
non-myocyte fraction in murine hearts [6,7]. The medial layer of small and large vessels consists
of vascular smooth muscle cells (VSMCs). Endothelial dysfunction is frequent in CKD [32] and can
be considered an early manifestation of coronary vascular disease [33]. Endothelial dysfunction
leads to disturbed microcirculation and is considered an independent risk factor for cardiovascular
events [33,34]. CKD-induced microangiopathy has been shown to lead to tissue hypoxia and
dysfunctional angiogenesis [33].
2.4. Oxidative Stress
Oxidative stress in CKD results from an imbalance in reactive oxygen species production and
impaired antioxidant defense [35]. Various oxidation products have been shown to be overabundant
in CKD. Increased ROS production has been reported to contribute to myocardial hypertrophy and
fibrosis by lipid peroxidation, proinflammatory cytokines and DNA damage [35,36]. A marker of
oxidative stress, 8-isoprostane, increases as CKD progresses [37]. Furthermore, NADPH oxidase
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generates reactive oxygen species, and this in turn leads to endothelial dysfunction [38]. Another effect
of elevated oxidative stress is the oxidation of plasma proteins, which causes activation of phagocytes
and increases inflammation [39]. Advanced oxidation protein products promote cardiomyocyte
apoptosis. This process is mediated by upregulation of c-Jun N-terminal kinase (JNK) signaling and
enhanced endoplasmic reticulum stress [40].
2.5. Inflammation
CKD can be seen as a state of increased systemic inflammation with various cytokines being among
the recognized uremic toxins. The Chronic Renal Insufficiency Cohort Study (CRIC) study found that
elevated plasma levels of high-sensitivity C-reactive protein (hs-CRP) and IL-6 were associated with LVH
and systolic dysfunction in CKD patients [41]. Freise et al. stated that, amongst others, inflammatory
processes involving tumor necrosis factor (TNF) and IL-10 impact pathobiological responses in arteries
from children with CKD, and are thus associated with tissue remodeling and cardiovascular disease [42].
Furthermore, CKD patients develop endotoxemia, characterized by elevated levels of endotoxin, IL-6,
CRP and lipopolysaccharide-binding protein (LBP), which contributes to chronic inflammation and
has been associated with higher left-ventricular mass index (LVMI) and subsequently left-ventricular
dysfunction [43]. Most of the soluble factors mentioned here are described as being secreted by cells
of the heart (cardiomyocytes, endothelial cells, fibroblasts, VSMCs and pericytes) but also resident
immune cells (e.g., macrophages, dendritic cells) and/or circulating cells might contribute to this. Thus,
the contribution of inflammatory cells to the described mechanisms cannot be excluded.
2.6. Advanced Glycation end Products
The soluble receptor for advanced glycation end-products (sRAGE) seems to play an important
role in cardiac remodeling in CKD patients. sRAGE has been described as a prognostic factor for
mortality in diabetic dialysis patients [43,44]. Elevated sRAGE concentrations could represent a
protective mechanism against the increased risk of cardiovascular complications resulting from AGEs
and inflammation, although the underlying mechanisms need to be further confirmed [45]. It has also
been shown that AGEs are involved in the upregulation of fibroblast growth factor 23 (FGF23).
In addition, cardiomyocytic FGF23 expression has been shown to be induced by activated renin-
angiotensin aldosterone system (RAAS) [46]. In turn, FGF23-mediated activation of local RAAS in
the heart promotes cardiac hypertrophy and fibrosis [47]. This finding underlines the organ crosstalk
between the kidney and heart in CKD-CVD.
2.7. Growth Factors
In addition to the above-mentioned metabolic and inflammatory pathways, several growth
factors might play important roles in cardiac fibrosis in CKD. One of the profibrotic modulators
that stimulates fibroblast proliferation is FGF2. FGF2 binds to FGF-receptor (FGFR) 1, which is
expressed in human cardiomyocytes. Additionally, FGF2 has been shown to promote growth of
isolated cardiomyocytes [47,48] and cardiac hypertrophy in rats following myocardial infarction [49],
thus further contributing to the cardiac phenotype in the cardiorenal syndrome. Another important
growth factor-based mechanism of cardiac fibrosis development was found by analyzing human heart
specimens. A marked reduction in cardiac Klotho, often found in CKD patients, was associated with
increased TGF-β signaling. This in turn upregulated Wnt signaling, a major pathway in fibrosis. This
was confirmed by in vitro studies with cardiomyocytes, where upregulation of endogenous Klotho
inhibited Wnt/β-catenin signaling [50].
2.8. FGF23
FGF23 is a phosphaturic hormone primarily secreted by osteocytes. Its main actions are maintaining
phosphate and mineral homeostasis. Furthermore, FGF23 decreases the synthesis of calcitriol. Its level
rises early and dramatically with the decline of kidney function [51]. FGF23 has effects on various
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organs. Numerous studies have shown a correlation between serum FGF23 and cardiac alterations
in CKD patients [52–58]. FGF23 directly induces LVH independent of preserved or reduced renal
function; this has been shown in vitro in cultured cardiomyocytes and by in vivo studies in mice, as
well as by correlations of circulating FGF23 levels with LVH in CKD patients [55]. FGF23 stimulates
pro-fibrotic and pro-hypertrophic factors in cardiomyocytes and induces fibrosis-related pathways
in fibroblasts [55,59,60]. In addition to its direct effects on cardiac remodeling, FGF23 has also been
shown to increase blood pressure [61], inflammation [62] and CKD progression itself [63], and may
thus promote the development of LVH also by indirect mechanisms. FGF23 signaling in the liver
causes production of inflammatory cytokines. In the bone, FGF23 inhibits mineralization, leading to
increased circulating phosphorus levels while reducing the production of erythropoietin (EPO) in the
bone marrow [64]. All of the above-mentioned actions affect the outcome of CKD patients, and thus
directly or indirectly lead to progression of cardiovascular disease.
2.9. Klotho
Membrane-bound Klotho serves as a co-receptor for FGF23 signaling and is synthesized in the
kidney and bone. Soluble Klotho shows endocrine actions correlated with anti-aging effects [65].
Soluble Klotho levels are decreased in CKD [65]. Using Klotho-deficient mice, it could be shown
that the Klotho-FGF23 axis plays a key role in pathologic cardiac remodeling in CKD, but also in
phosphotoxicity and aging [66]. In pediatric CKD patients, serum FGF23 levels increased and Klotho
levels decreased with progressing renal failure, while phosphorus levels were maintained in the
normal range [67]. In those patients, high FGF23 and low Klotho levels were strongly associated
with impaired left ventricular diastolic function [67]. In addition to this finding, FGF23 signaling
via fibroblast growth factor receptor 4 (FGFR4) activates the phospholipase Cγ/calcineurin/nuclear
factor of the activated T-cell pathway, and thus promotes cardiac myocyte hypertrophy, independent
of its co-receptor Klotho [60,67]. Furthermore, FGFR4 signaling is responsible for FGF23-mediated
increased cardiac contractility [68]. Correspondingly, aging mice lacking FGFR4 were protected from
LVH. Thus, FGF23/FGFR4 signaling plays an important role in the regulation of cardiac remodeling and
function [68]. Additionally, pharmacological blockade of the FGF receptor improved cardiac structure
and function in 5/6 nephrectomy rats, thus underlining the role of FGFR activation as a mechanism of
LVH in CKD [59].
2.10. Uremic Toxins
The role of uremic toxins in the development of cardiac remodeling is less well established. Recent
work sheds light on the potential roles of asymmetric dimethylarginine (ADMA), advanced glycation
end-products (AGE), trimethylamine N-oxide (TMAO) and indoxyl sulfate [69]. ADMA has been
reported to be involved in regulation of nitric oxide, reactive oxygen species and renal anemia [69,70].
The AGE/RAGE axis is responsible for cell damage in CVD [69], driving cardiac fibrosis. TMAO, a
metabolite derived from choline, is linked with left-ventricular diastolic dysfunction [71] and cardiac
fibrosis [69].
In addition, several other uremic toxins are also thought to promote the cardiorenal syndrome
by direct cardiotoxicity, including indoxyl sulfate and p-cresyl sulfate [71,72]. Indoxyl sulfate is a
product of the intestinal catabolism of tryptophan with insufficient dialytic removal, as it is bound to
albumin in the blood. In uremia, it increases up to 88-fold [73] and has been shown to mediate immune
dysfunction and cytotoxic effects on endothelial cells in patients with end-stage renal disease [74].
Indoxyl sulfate stimulates the cannabinoid receptor type 1 and was associated with fibrotic effects via
modulation of Akt signaling in myofibroblasts [75].
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Table 1. Some systemic factors that have been reported to be involved in uremic cardiomyopathy.
Factor References
Phosphate Homeostasis
FGF23/Klotho [46,47,50,52–60,67,68,76]
Vit D receptor agonists [77,78]
Uremic Toxins
p-Cresylsulfate [72]
Indoxylsulfate [72,75]
ADMA [69,70]
Growth Factors
TGF-β [50]
FGF2 [48,49]
EPO [64,79,80]
Metabolic Stress
AGE [44,45,69]
ROS [36,38,40,81–83]
PPARα [84]
TMAO [69,71]
Inflammation
S100/calgranulin [85,86]
Interleukin 6 [43]
Interleukin 10 [42]
CRP [41]
TNF [42]
Several studies have pointed towards a role of uremic toxins in cardiac remodeling, however, the
complex mechanisms of cell-type activation that drive cardiac fibrosis, hypertrophy and capillary loss
are still unclear. Further studies using state-of-the-art single-cell technologies may shed more light on
this important disease that affects numerous CKD/ESRD patients.
3. Mouse Models of Cardiac Remodeling in CKD
To date, most animal studies investigating mechanisms and interventions in the cardiorenal
syndrome have been performed in rats. The models employed (5/6 nephrectomy, adenine nephropathy,
ischemia reperfusion injury, etc.) are well established and cause reliable cardiac remodeling. However,
mouse models do offer some advantages, the most important of which is the possibility of generating
genetic modifications, which enable the analysis of specific pathways and molecular mechanisms. Thus,
improving mouse models of CKD-CVD is one important goal in order to clarify the pathogenesis of
the cardiorenal syndrome and develop novel therapies for patients. Several attempts have been made
to establish CKD-CVD in mice. They can be divided into three approaches: surgical interventions,
chemical interventions and genetic interventions. Table 2 summarizes the kidney parameters and
functional and structural cardiac parameters of murine CKD-CVD studies.
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Table 2. Functional and structural cardiac parameters in mouse models of chronic kidney disease (CKD). GFR—glomerular filtration rate, sCr—serum creatinine,
BUN—blood urea nitrogen, EF—ejection fraction, FS—fractional shortening, SV—stroke volume, CO—cardiac output, BP—blood pressure, LVH—left-ventricular
hypertrophy, Nx—nephrectomy, AT1—angiotensin II type-1A receptor, UUO—unilateral ureteral obstruction, hBAC-S100—bacterial artificial chromosome of the
human S100/calgranulin gene cluster, Col4a3—collagen type IV alpha 3 chain, n.d.—not determined, wk—week.
Kidney Heart (Functional) Heart (Structural)
Model MouseStrain
Duration
(Weeks) GFR sCr BUN EF/FS SV/CO BP LVH Fibrosis Capillary Loss References
surgically induced
5/6 Nx (2-step) C57BL/6 8 n.d. ↑ ↑ - ↓ n.d. ↑ ↑ n.d. [75]
5/6 Nx (2-step) C57BL/6 12 n.d. ↑ ↑ ↓ n.d. n.d. ↑ ↑ ↑ [87]
AT1 knockout, 5/6 Nx
(2-step) C57BL/7 12 n.d. ↑ ↑ ↓ n.d. n.d. ↑ ↑ - [87]
5/6 Nx (2-step) C57BL/6 12 n.d. ↑ ↑ ↓ n.d. - ↑ ↑ ↑ [79]
5/6 Nx (2-step) 129X1/SvJ 16 n.d. n.d. ↑ - n.d. ↑ ↑ ↑ n.d. [88]
5/6 Nx (2-step, pole
ligation) C57BL/6 4 n.d. ↑ ↑ n.d. n.d. n.d. ↑ ↑ n.d. [89]
5/6Nx (1-step) BALB/c 8, 16 and 24 n.d. n.d. ↑ (8, 16, 24 wk) ↓ (24 wk) n.d. ↑ (16, 24 wk) n.d. ↑ (24 wk) n.d. [90]
5/6Nx (1-step) CD1 4, 6 and 8 n.d. n.d. n.d. ↑ n.d. ↑ ↑ ↑ n.d. [91]
UUO C57BL/6 3 n.d. ↑ ↑ - n.d. ↑ ↑ ↑ - [92]
hBAC-S100, UO C57BL/6 10 n.d. n.d. ↑ - n.d. ↑ ↑ n.d. n.d. [85]
129Sv 10 ↓ ↑ ↑ ↓ ↓ ↑ - ↑ n.d.
chemically induced
0.15% adenine C57BL/6 20 ↓ ↑ ↑ ↓ n.d. n.d. ↑ ↑ n.d. [86]
10 mg/kg cisplatin +
high phosphate diet 129Sv 20 ↓ ↑ ↑ n.d. n.d. n.d. ↑ ↑ n.d. [93]
genetically induced
Col4a3 knockout C57BL/6 10 and 20 ↓ ↑ ↑ - ↓ (only 20 wk) ↑ (only 10 wk) ↑ (only 20 wk) ↑ (only 20 wk) n.d. [94]
↓: reduced in comparison to control animals ↑: increased in comparison to control animals.
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3.1. Surgically Induced Models
The most well-characterized surgical model is the subtotal nephrectomy model, also called
5/6 nephrectomy. There are different methods for performing this surgery; all involve unilateral
nephrectomy. Reduction of the remaining kidney mass is then performed either by cauterization,
ligation or slicing off the two poles, or by occlusion of the branches of the main kidney artery. Unilateral
nephrectomy and reduction of the remaining kidney mass are either performed on the same day
(1-step) or with a 7- to 14-day recovery phase after the unilateral nephrectomy (2-step). Various studies
describe a cardiac phenotype resulting from CKD in these mice, which is aggravated with the time
elapsed since surgery (see Table 2). The surgically induced model has been reported to mimic most
phenotypic changes observed in the human disease. However, the resulting phenotype is highly
dependent on the genetic background of the mice.
A study performed in nephrectomized C57BL/6 mice showed impaired renal function, anemia,
cardiac hypertrophy, cardiac fibrosis and decreased systolic and diastolic heart function compared to
sham-operated mice [75,89]. In addition, there was increased expression of natriuretic peptides, another
marker of progressive heart failure, in nephrectomized male 129X1/SvJ mice [88]. Subtotal nephrectomy
in male CD1 mice resulted in physiological and morphological changes that also mimicked the cardiac
phenotype in patients with CKD [91]. In a study with male BALB/c mice, analyzed for up to 24 weeks
after 5/6 nephrectomy, cardiac and arterial structure and function showed signs of fibrosis, oxidative
damage and endothelial dysfunction [90,91].
RAAS is a key player in blood-pressure control and has been described as being highly relevant in
the cardiorenal syndrome. Subtotal nephrectomy in angiotensin II type 1A receptor (AT1) knockout
mice resulted in significantly reduced cardiac hypertrophy, fibrosis and capillary rarefaction compared
to their wildtype littermates [87]. Other widely used cardioprotective and antihypertensive treatments
such as β1-receptor blockers have also been shown to reduce cardiac hypertrophy in CKD [95].
CKD patients suffer from reduced erythropoietin (EPO) levels, and it has been shown that besides
causing anemia, EPO reduction had direct effects on the cardiovascular system of these patients. In
line with this, 5/6 nephrectomized mice receiving recombinant human erythropoietin (rhEPO) had a
better outcome compared to saline-treated controls in terms of cardiac function and remodeling. These
effects were independent of anemia. Thus, a control group that received an EPO derivate (asialo-EPO)
still suffered from anemia but showed the same beneficial effects on cardiac remodeling [79,95]. Both
compounds similarly attenuated LVH, indicating that EPO receptor signaling protected the hearts
of CKD mice through mechanisms independent of erythropoiesis. The production of erythrocytes
requires continuous stimulation of EPO receptors, whereas a brief stimulation is described to be
sufficient for neuroprotection. The same mechanism might explain the cardioprotective effect in this
model [79].
In addition, unilateral ureteral obstruction (UUO) can induce some cardiac hypertrophy and
fibrosis [79,92]. However, since UUO does not cause renal failure in the presence of a non-injured
contralateral kidney, the model is probably not suitable to induce a severe cardiac phenotype.
By performing a graded ureter obstruction model in combination with a systemic expression of
humanized S100A8, S100A12, and S100A9 in C57BL/6 mice, the association between S100/RAGE/FGF23
and cardiac hypertrophy was revealed [85]. Elevated serum concentrations of S100A12 are associated
with inflammatory diseases, and thus might accelerate pathological cardiac remodeling in CKD
patients. As mice do not express S100A12 [34,96], a humanized model was generated and CKD was
induced via reversible unilateral ureteral obstruction. For this method, the right ureter was obstructed
using a clip that was relocated every other day to prevent irreversible obstruction. After 7 days, the
clip was removed to allow recovery of the right kidney, followed by irreversible ligation of the left
ureter. A potential mechanism to explain the results of the study was presented with the finding
that in addition to osteocyte expression, in CKD patients, FGF23 is also expressed in the heart by
cardiomyocytes, cardiac fibroblasts, vascular smooth muscle cells and endothelial cells in coronary
arteries, and by inflammatory macrophages [60]. It was suggested that S100/RAGE-mediated chronic
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sustained systemic inflammation caused cardiac fibroblasts to upregulate FGF23 synthesis, and in turn,
increased cardiac FGF23 levels were linked to pathological cardiac remodeling [86].
3.2. Chemically Induced Models
Surgical methods to induce CKD associated with cardiovascular changes are often accompanied
by a high mortality and require well-trained surgeons. Thus, efforts have been made to establish
non-surgical techniques for CKD induction. One option is to apply orally administered adenine, which
is metabolized to 2,8-dihydroxyadenine, and which in turn precipitates as crystals in the renal proximal
tubular epithelium causing inflammation and fibrosis, ultimately leading to CKD. Indeed, mice treated
with adenine developed symptoms of the cardiorenal syndrome, in particular cardiac hypertrophy,
impaired cardiac function, as well as increased fibrosis [97].
An additional chemically induced model for murine CKD-CVD was achieved in mice via a
single injection of cisplatin and subsequent feeding of a high-phosphate diet. CKD was confirmed by
decreased creatinine clearance, development of interstitial kidney fibrosis, hyperphosphatemia, high
plasma levels of PTH and FGF23 and low levels of plasma calcitriol and αKlotho. The mice developed
LVH and cardiac fibrosis. This model resembles the transition from acute kidney injury to chronic
renal failure and thus displays a promising approach to study underlying mechanisms in humans [93].
3.3. Genetically Induced Models
In addition to the above-mentioned models for CKD induction, CVD has also been reported in
genetic mouse models of CKD. One example is the Alport mouse model, i.e., murine Col4a3 deficiency.
The phenotype of C57BL/6 Col4a3 knockout mice was milder than that of 129Sv mice, which correlated
with prolonged survival of the C57BL/6 mice. After 20 weeks, the C57BL/6 mice developed CKD
associated with functional and structural symptoms of cardiac remodeling [94]. This emphasizes the
importance of the genetic background of the mice used in relation to the severity of cardiac disease.
For example, C57BL/6 mice usually have much milder phenotypes compared to 129Sv mice.
4. Potential Therapeutic Targets of Cardiac Remodeling in CKD
Reduction or inhibition of LVH might be achieved by non-specific treatments such as reduction of
hypervolemia, lowering of blood pressure and treatment with angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers that exhibit potential direct effects on the myocardium [16,94]. Further
strategies to prevent left-ventricular remodeling in patients with mild-to-moderate CKD comprise of
reducing overweightness and avoiding hemoglobin concentrations that are too high [98].
Paricalcitol, a vitamin D receptor agonist, has shown a beneficial effect on myocardial fibrosis
in rats [77,78]. However, in CKD patients, paricalcitol administration failed to improve diastolic
function [99,100].
As oxidative stress triggers cardiovascular remodeling, antioxidative therapies have been proposed
to protect endothelial cells from reactive oxygen species, thereby preventing endothelial dysfunction.
Quercetin and antioxidant enzyme mimetics were shown to inhibit the NFkB pathway and reduce
ROS generation in an in vitro assay using endothelial cells [101]. Several studies have attempted
to reduce imbalances caused by oxidative stress in cardiac remodeling in CKD. Accordingly, Liu et
al. demonstrated that antagonism of the Na/K-ATPase ameliorates uremic cardiomyopathy in 5/6
nephrectomized mice [81,82]. Na/K-ATPase activation leads to increased ROS production and acts
as a signal transducer inside cardiomyocytes [81]. In activated Na/K-ATPase signaling, microRNA
29b-3b is downregulated, and thus fails to inhibit collagen expression, which has been shown in
cardiac fibroblasts [81,83]. Na/K-ATPase is also known to stimulate mTOR signaling, thereby activating
pro-fibrotic pathways. Moreover, the mTOR inhibitor rapamycin has been shown to inhibit cardiac
fibrosis in rats [102].
As some of the uremic toxins are derived from intestinal bacteria, the microbiome could be another
potential target in the cardiorenal syndrome. Thus, indoxyl sulfate and para-Cresyl sulfate serum
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levels were reduced by antibiotic therapy in ESRD patients [103,104]. Indoxyl sulfate binds to the
cannabinoid receptor [75]. Interestingly, inhibition of this receptor has also been shown to reduce
cardiac fibrosis in 5/6 nephrectomized mice [75].
FGF23 promotes cardiac fibrosis and LVH. Additionally, FGF23 signaling in the liver causes the
production of inflammatory cytokines. In the bone, FGF23 inhibits mineralization, leading to increased
circulating phosphorus levels and a reduction in the production of EPO [64,75]. Thus, the identification
of FGF23 receptors in the respective organs will be crucial in future research since their selective
blockade could be considered as a therapeutic target [64]. On the other hand, FGF23 antibody treatment
caused mineral disturbances, in particular hyperphosphatemia and was associated with increased
mortality in a CKD rat model [105]. Recombinant Klotho was used in an experimental mouse model to
attenuate cardiac remodeling and reduce cardiac and renal fibrosis [105,106]. A positive correlation
between FGF23 and cardiac hypertrophy exists in a Klotho-deficient state, but not in a Klotho-repleted
state [76,105,106]. In addition, pharmacological interference with cardiac FGF23/FGFR4 signaling
might have a protective effect on CKD- and age-related LVH [68]. First studies in rats report that
pharmacological inhibition of FGFR might be a potent blood pressure-independent mechanism to
prevent LVH in CKD [59].
CKD patients have low EPO levels, which are associated with cardiac fibrosis. A study in
5/6 nephrectomized rats showed that EPO in combination with enalapril reduced cardiac fibrosis
and capillary rarefaction. The underlying mechanisms are likely multifactorial but may encompass
decreased myocardial oxidative stress [81]. In CKD patients, there is better survival in those treated
with EPO to a hemoglobin level of 10-12 g/dl, whereas normalization of hemoglobin levels was not
beneficial [80,107].
Calò et al. identified rho kinase (ROCK) activation as a potential LVH marker in CKD patients,
which indicates that inhibition of ROCK activation might serve as a target to treat cardiac remodeling
in those patients [108].
A study performed in 5/6 nephrectomized rats treated with the PPARα agonist clofibrate did
indeed reveal improved cardiac function and prevention of LVH [84].
Finally, restoring kidney function can at least partially reverse cardiac changes. It has been shown
by echocardiography that a kidney transplantation improves left-ventricular function [103].
In conclusion, to date, few specific therapies exist that can inhibit cardiac remodeling in CKD. A
better understanding of the cell types involved and their mechanisms of activation, e.g., by crosstalk or
presumed uremic toxins, will guide the development of urgently needed novel therapeutics.
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